Filgastrim: Difference between revisions
(Created page with "{{DrugProjectFormSinglePage |genericName=Filgastrim |aOrAn=a |drugClass=colony stimulating factor |indicationType=treatment |indication=severe neutropenia in patients...") |
No edit summary |
||
| Line 30: | Line 30: | ||
====Potential for Tumor Growth Stimulatory Effects on Malignant Cells==== | ====Potential for Tumor Growth Stimulatory Effects on Malignant Cells==== | ||
*The [[granulocyte colony-stimulating factor]] ([[G‑CSF]]) receptor through which GRANIX acts has been found on tumor cell lines. The possibility that GRANIX acts as a growth factor for any tumor type, including [[myeloid malignancies]] and [[myelodysplasia]], diseases for which GRANIX is not approved, cannot be excluded. | *The [[granulocyte colony-stimulating factor]] ([[G‑CSF]]) receptor through which GRANIX acts has been found on tumor cell lines. The possibility that GRANIX acts as a growth factor for any tumor type, including [[myeloid malignancies]] and [[myelodysplasia]], diseases for which GRANIX is not approved, cannot be excluded. | ||
|clinicalTrials='''Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.''' | |||
GRANIX clinical trials safety data are based upon the results of three randomized clinical trials in patients receiving myeloablative chemotherapy for [[breast cancer]] (N=348), [[lung cancer]] (N=240) and [[non-Hodgkin’s lymphoma]] (N=92). In the [[breast cancer]] study, 99% of patients were female, the median age was 50 years, and 86% of patients were Caucasian. In the [[lung cancer]] study, 80% of patients were male, the median age was 58 years, and 95% of patients were Caucasian. In the non-Hodgkin’s lymphoma study, 52% of patients were male, the median age was 55 years, and 88% of patients were Caucasian. In all three studies a [[placebo]] (Cycle 1 of the [[breast cancer]] study only) or a non-US-approved filgrastim product were used as controls. Both GRANIX and the non-US-approved filgrastim product were administered at 5 mcg/kg subcutaneously once daily beginning one day after chemotherapy for at least five days and continued to a maximum of 14 days or until an [[ANC]] of ≥10,000 x 106/L after nadir was reached. | |||
[[Bone pain]] was the most frequent treatment-emergent adverse reaction that occurred in at least 1% or greater in patients treated with GRANIX at the recommended dose and was numerically two times more frequent than in the placebo group. Theoverall incidence of bone pain in Cycle 1 of treatment was 3.4% (3.4% GRANIX, 1.4% placebo, 7.5% non-US-approved filgrastim product). | |||
=====Leukocytosis===== | |||
*In clinical studies, [[leukocytosis]] (WBC counts > 100,000 x 106/L) was observed in less than 1% patients with non-myeloid malignancies receiving GRANIX. No complications attributable to leukocytosis were reported in clinical studies. | |||
=====Additional Adverse Reactions===== | |||
*Other adverse reactions known to occur following administration of human [[granulocyte colony-stimulating factors]] include [[myalgia]], [[headache]], [[vomiting]], [[Sweet’s syndrome]] (acute [[febrile neutrophilic dermatosis]]), [[cutaneous vasculitis]] and [[thrombocytopenia]]. | |||
|drugInteractions=*No formal drug interaction studies between GRANIX and other drugs have been performed. | |||
*Drugs which may potentiate the release of neutrophils‚ such as lithium‚ should be used with caution. | |||
*Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone-imaging results. | |||
|overdose=No case of overdose has been reported. | |||
|alcohol=Alcohol-Filgastrim interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | |alcohol=Alcohol-Filgastrim interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | ||
}} | }} | ||
Revision as of 17:01, 11 February 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Filgastrim is a colony stimulating factor that is FDA approved for the treatment of severe neutropenia in patients with non‑myeloid malignancies receiving myelosuppressive anti‑cancer drugs associated with a clinically significant incidence of febrile neutropenia. Common adverse reactions include bone pain.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
There is limited information regarding Filgastrim FDA-Labeled Indications and Dosage (Adult) in the drug label.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Filgastrim in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Filgastrim in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Filgastrim FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Filgastrim in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Filgastrim in pediatric patients.
Contraindications
None
Warnings
Splenic Rupture
- Splenic rupture, including fatal cases, can occur following administration of human granulocyte colony-stimulating factors. In patients who report upper abdominal or shoulder pain after receiving GRANIX, discontinue GRANIX and evaluate for an enlarged spleen or splenic rupture.
Acute Respiratory Distress Syndrome (ARDS)
- Acute respiratory distress syndrome (ARDS) can occur in patients receiving human granulocyte colony-stimulating factors. Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving GRANIX, for ARDS. Discontinue GRANIX in patients with ARDS.
Allergic Reactions
- Serious allergic reactions including anaphylaxis can occur in patients receiving human granulocyte colony-stimulating factors. Reactions can occur on initial exposure. The administration of antihistamines‚ steroids‚ bronchodilators‚ and/or epinephrine may reduce the severity of the reactions. Permanently discontinue GRANIX in patients with serious allergic reactions. Do not administer GRANIX to patients with a history of serious allergic reactions to filgrastim or pegfilgrastim.
Use in Patients with Sickle Cell Disease
- Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disease receiving human granulocyte colony-stimulating factors. Consider the potential risks and benefits prior to the administration of human granulocyte colony-stimulating factors in patients with sickle cell disease. Discontinue GRANIX in patients undergoing a sickle cell crisis.
Capillary Leak Syndrome
- Capillary leak syndrome (CLS) can occur in patients receiving human granulocyte colony-stimulating factors and is characterized by hypotension, hypoalbuminemia, edema and hemoconcentration. Episodes vary in frequency, severity and may be life-threatening if treatment is delayed. Patients who develop symptoms of capillary leak syndrome should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care.
Potential for Tumor Growth Stimulatory Effects on Malignant Cells
- The granulocyte colony-stimulating factor (G‑CSF) receptor through which GRANIX acts has been found on tumor cell lines. The possibility that GRANIX acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which GRANIX is not approved, cannot be excluded.
Adverse Reactions
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
GRANIX clinical trials safety data are based upon the results of three randomized clinical trials in patients receiving myeloablative chemotherapy for breast cancer (N=348), lung cancer (N=240) and non-Hodgkin’s lymphoma (N=92). In the breast cancer study, 99% of patients were female, the median age was 50 years, and 86% of patients were Caucasian. In the lung cancer study, 80% of patients were male, the median age was 58 years, and 95% of patients were Caucasian. In the non-Hodgkin’s lymphoma study, 52% of patients were male, the median age was 55 years, and 88% of patients were Caucasian. In all three studies a placebo (Cycle 1 of the breast cancer study only) or a non-US-approved filgrastim product were used as controls. Both GRANIX and the non-US-approved filgrastim product were administered at 5 mcg/kg subcutaneously once daily beginning one day after chemotherapy for at least five days and continued to a maximum of 14 days or until an ANC of ≥10,000 x 106/L after nadir was reached.
Bone pain was the most frequent treatment-emergent adverse reaction that occurred in at least 1% or greater in patients treated with GRANIX at the recommended dose and was numerically two times more frequent than in the placebo group. Theoverall incidence of bone pain in Cycle 1 of treatment was 3.4% (3.4% GRANIX, 1.4% placebo, 7.5% non-US-approved filgrastim product).
Leukocytosis
- In clinical studies, leukocytosis (WBC counts > 100,000 x 106/L) was observed in less than 1% patients with non-myeloid malignancies receiving GRANIX. No complications attributable to leukocytosis were reported in clinical studies.
Additional Adverse Reactions
- Other adverse reactions known to occur following administration of human granulocyte colony-stimulating factors include myalgia, headache, vomiting, Sweet’s syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitis and thrombocytopenia.
Postmarketing Experience
There is limited information regarding Filgastrim Postmarketing Experience in the drug label.
Drug Interactions
- No formal drug interaction studies between GRANIX and other drugs have been performed.
- Drugs which may potentiate the release of neutrophils‚ such as lithium‚ should be used with caution.
- Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone-imaging results.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Filgastrim in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Filgastrim in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Filgastrim during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Filgastrim in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Filgastrim in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Filgastrim in geriatric settings.
Gender
There is no FDA guidance on the use of Filgastrim with respect to specific gender populations.
Race
There is no FDA guidance on the use of Filgastrim with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Filgastrim in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Filgastrim in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Filgastrim in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Filgastrim in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Filgastrim Administration in the drug label.
Monitoring
There is limited information regarding Filgastrim Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Filgastrim and IV administrations.
Overdosage
No case of overdose has been reported.
Pharmacology
There is limited information regarding Filgastrim Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Filgastrim Mechanism of Action in the drug label.
Structure
There is limited information regarding Filgastrim Structure in the drug label.
Pharmacodynamics
There is limited information regarding Filgastrim Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Filgastrim Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Filgastrim Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Filgastrim Clinical Studies in the drug label.
How Supplied
There is limited information regarding Filgastrim How Supplied in the drug label.
Storage
There is limited information regarding Filgastrim Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Filgastrim |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Filgastrim |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Filgastrim Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Filgastrim interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Filgastrim Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Filgastrim Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.